Longevity.Technology’s Post

Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics: The Key Vascular Ehlers-Danlos Syndrome Companies in the market include – Aytu BioPharma, Acer Therapeutics, and others.   The Vascular Ehlers-Danlos Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

The FDA on Friday signed off on Pfizer’s marstacimab-hncq for the treatment of hemophilia A or hemophilia B in adults or adolescents, which will now be marketed under the brand name Hympavzi. Friday’s approval makes Hympavzi the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S., according to Pfizer’s announcement. Hympavzi is also the first treatment available through a pre-filled pen or syringe for both hemophilia A and hemophilia B. Hympavzi’s approval comes as Pfizer continues to grapple with activist investor Starboard Value which last week took a $1 billion stake in the pharma, hoping to depose CEO Albert Bourla and shake up the direction of the company. However, former Pfizer CEO Ian Read and former CFO Frank D’Amelio reaffirmed their support for the company’s current leadership. Starboard Value in a letter to Pfizer’s board claimed Read and D’Amelio were pressured to issuing a statement of support for Bourla and senior management. #biotech #biopharma #pharma #FDA #Approval

This is an insanely smart approach to drug discovery: SFA Therapeutics are focused on harnessing what they call "endogenous biosynthetic drugs", i.e. active pharmaceutical ingredients derived from bacterial metabolites found in humans ... Logically, the promise is no genotoxicity, faster clinical development and safer treatments ... and could lead to a new paradigm in drug discovery! 🧫🦠💊💪 ⇨ 👩⚕️🩺 Link to a recent article in Drug Target Review, "The promise of therapeutics from molecules within our body" https://lnkd.in/d2GNhMaY #drug #discovery #SFAtherapeutics #paradigm #endobacteria #translation #notox #safety #clinic #clinicaltrials #patientneed #impact #health #innovation #biotech #biopharma

📢 New Review Alert! 🚀 We are excited to share our latest review article on "Prevention of Paclitaxel-Induced Peripheral Neuropathy: A Literature Review of Potential Pharmacological Interventions," published in the Future Journal of Pharmaceutical Sciences. 🧬✨ 🔬 Key Highlights: Paclitaxel is a cornerstone chemotherapy for many cancers but often causes debilitating peripheral neuropathy. Our review covers promising preclinical and clinical studies exploring various pharmacological agents for PIPN prevention. Antioxidants, anti-inflammatory agents, nutritional supplements, and more are showing potential in reducing PIPN incidence and severity. 🧪 Why It Matters: Up to 97% of patients on paclitaxel experience peripheral neuropathy, impacting their quality of life and treatment outcomes. Identifying effective preventive measures is crucial for improving patient care. 🙏 Special Thanks: A huge thank you to all my co-authors for their invaluable contributions to this work. A special acknowledgment to Dr. Aalaa Mahmoud El-Rifai, BSc. for her exceptional efforts and dedication throughout this research. 📖 Read the full article here: https://lnkd.in/defKaKcV #CancerResearch #Chemotherapy #Paclitaxel #PeripheralNeuropathy #Pharmacology #Oncology #MedicalResearch #FutureScience

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) by Vertex FDA Approval to Treat Cystic Fibrosis (CF) FDA approved Alyftrek in December 2024. Alyftrek is a once daily oral medication used to treat CF in patients aged 6 and older: It's approved for patients with at least one F508del mutation or another mutation in the CFTR gene that responds to Alyftrek. It's the fifth CFTR modulator to receive FDA approval. Some important safety information about Alyftrek includes: It shouldn't be used by patients with severe hepatic impairment (Child-Pugh Class C). It's not recommended for patients with moderate hepatic impairment (Child-Pugh Class B), but it can be considered if the benefit outweighs the risk. Patients should be closely monitored if Alyftrek is used. https://lnkd.in/gfTT9bnM. #HealthCare #Pharmacy #ClinicalTrials #CysticFibrosis #CF #Vanzacaftor #Tezacaftor #Deutivacaftor #Alyftrek #Vertex

𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐖𝐨𝐥𝐟𝐫𝐚𝐦 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞: 𝐀𝐌𝐗𝟎𝟎𝟑𝟓 𝐒𝐡𝐨𝐰𝐬 𝐏𝐫𝐨𝐦𝐢𝐬𝐞 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Amylyx Pharmaceuticals shared interim data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome. Eight participants completing 24 weeks of treatment showed promising results, including improvements in diabetes progression, visual decline, and overall disease burden. Lead investigator Dr. Fumihiko Urano Fumihiko Urano highlighted the urgent need for disease-modifying treatments in Wolfram syndrome. AMX0035 demonstrated meaningful effects across multiple organ systems affected by the disease. The ongoing HELIOS trial assesses AMX0035's ability to slow disease progression and evaluate safety in 12 participants. Interim analysis showed increases in pancreatic beta cell function and glycemic control, contrary to the expected decline in Wolfram syndrome. AMX0035 targets endoplasmic reticulum (ER) stress and mitochondrial dysfunction, addressing key aspects of Wolfram syndrome pathology. Promising results align with preclinical data and support AMX0035's potential in treating Wolfram syndrome. Further analysis revealed improvements in hemoglobin A1C, time in target glucose range, and visual acuity. All participants showed disease stability or improvement, with a favorable safety profile consistent with prior data. AMX0035 received orphan drug designation from the FDA in November 2020. Amylyx plans to engage with regulatory authorities and expects topline data for all participants by the second half of the year. #WolframSyndrome #AMX0035 #HELIOSTrial #RareDisease #ClinicalTrial #OrphanDrug #MedicalResearch #Healthcare #AmylyxPharmaceuticals

COYA 302 is a therapy that combines two different biologics — low-dose IL-2 and CTLA-4 Ig. Complex diseases demand complex treatment solutions, and the combination biologic approach is key in our hypothesis to treat neurodegenerative diseases like ALS. Learn more about the approach in this article from Bioprocess Online: https://lnkd.in/emyC3eys $COYA #CoyaTherapeutics #CombinationBiologics

Thoughts on this? >> Kezar halts dosing and enrollment in key lupus study after 4 patient deaths >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #competitivemarketing #pharmaceutical #pharma

Giroctocogene Fitelparvovec Reduces Total Annualized Bleeding Rate for Hemophilia A: The investigational drug achieved non-inferiority compared to routine Factor VIII. #finance #pharmacy #lifesciences

Thoughts on this? >> Kezar halts dosing and enrollment in key lupus study after 4 patient deaths >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #healthcare #competitivemarketing